Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study

Multiple Myeloma (MM)

Predicting Venous Thromboembolism in Multiple Myeloma: Development and Validation of the IMPEDE VTE Score

Am J Hematol.

Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM, Mikhael J, Kuderer NM, Calverley D, Keller J, Thomas T, Carson KR, Gage BF

doi: 10.1002/ajh.25603.

A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts

Lancet Haematol.

Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, Di Nisio M, Cesarman-Maus G, Kraaijpoel N, Zielinski CC, Büller HR, Ay C

doi: 10.1016/S2352-

Lymphoma

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

Lancet Oncol.

Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G

doi: 10.1016/S1470-2045

RECOMMENDED

Leukemia

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

Lancet Haematol.

Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD

doi: 10.1016/S2352-3026(19)30085-7.

Further Publications

Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry

Lancet Haematol

Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard JE, Giebel S, Gilleece MH, Giralt S, Jakubowski A, Montoto S, O'Reilly RJ, Papadopoulos EB, Peric Z, Ruggeri A, Sanz J, Sauter CS, Savani BN, Schmid C, Spyridonidis A, Tamari R, Versluis J, Yakoub-Agha I, Perales MA, Mohty M, Nagler A

doi: 10.1016/S2352-3026(20)30394-X

Multiple Myeloma (MM)

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis

Br J Haematol

Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, Mailankody S, Lesokhin A, Shah U, Lu S, Patel D, Derkach A, Wilkins CR, Korde N

doi: 10.1111/bjh.17772

Multiple Myeloma (MM)

Transplant eligibility in elderly Multiple Myeloma patients: prospective external validation of the International Myeloma Working Group (IMWG) frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years

Am J Hematol.

Belotti A, Ribolla R, Cancelli V, Crippa C, Bianchetti N, Ferrari S, Bottelli C, Cattaneo C, Tucci A, Barrigon CF, Rossi G

doi: 10.1002/ajh.25797.

Multiple Myeloma (MM)

Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study

Jing Luo, Joshua J. Gagne, Joan Landon, Jerry Avorn, Aaron S. Kesselheim

doi: 10.1016/j.ejca.2016.10.018

Gynecologic Cancer

Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study

Lancet Oncol

Braga A, Paiva G, Ghorani E, Freitas F, Velarde LGC, Kaur B, Unsworth N, Lozano-Kuehne J, Dos Santos Esteves APV, Rezende Filho J, Amim J Jr, Aguiar X, Sarwar N, Elias KM, Horowitz NS, Berkowitz RS, Seckl MJ

doi: 10.1016/S1470-2045(21)00262-X

Related content

Predicting Venous Thromboembolism in Multiple Myeloma: Development and Validation of the IMPEDE VTE Score

A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis

Transplant eligibility in elderly Multiple Myeloma patients: prospective external validation of the International Myeloma Working Group (IMWG) frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years

Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study

Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study